Diagen signs new distribution agreement with SpeeDx

Sydney, Australia-based SpeeDx has announced a distribution agreement with Scandinavian clinical laboratory supplier Diagen to supply its polymerae chain reaction product lines to hospitals and research facilities across Sweden, Norway and Denmark.

The PlexPCR® range will allow Diagen’s customers to obtain complex diagnostic information on sexually transmitted infections or other infectious diseases from a single, cost-effective test. The agreement will also give them access to the ResistancePlus MG assay. This is the first CE-IVD test to simultaneously detect Mycoplasma genitalium and genetic markers for azithromycin resistance, as recommended by the new European guidelines on M. genitalium resistance screening in the management of non-gonococcal urethritis.

“Scandinavia is home to some important thought leaders influencing sexual health and STI testing practices across Europe,” said Colin Denver, CEO of SpeeDx. “We see our partnership with Diagen as key to offering the best service to laboratories across these important markets.”